128 related articles for article (PubMed ID: 34507666)
21. Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions.
Kawarada Y; Miyazaki M; Itoh A; Araki R; Iwamizu H; Kataoka T; Kumakura Y; Ota A; Nagai T; Yamada K
Int J Clin Oncol; 2017 Jun; 22(3):593-599. PubMed ID: 28124284
[TBL] [Abstract][Full Text] [Related]
22. Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
J Cancer Res Clin Oncol; 2001 Jan; 127(1):55-8. PubMed ID: 11206272
[TBL] [Abstract][Full Text] [Related]
23. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience.
Lafay-Cousin L; Sung L; Carret AS; Hukin J; Wilson B; Johnston DL; Zelcer S; Silva M; Odame I; Mpofu C; Strother D; Bouffet E
Cancer; 2008 Feb; 112(4):892-9. PubMed ID: 18098210
[TBL] [Abstract][Full Text] [Related]
24. Clinical features of hypersensitivity reactions to carboplatin.
Markman M; Kennedy A; Webster K; Elson P; Peterson G; Kulp B; Belinson J
J Clin Oncol; 1999 Apr; 17(4):1141. PubMed ID: 10561172
[TBL] [Abstract][Full Text] [Related]
25. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies.
Koshiba H; Hosokawa K; Kubo A; Miyagi Y; Oda T; Miyagi Y; Watanabe A; Honjo H
Int J Gynecol Cancer; 2009 Apr; 19(3):460-5. PubMed ID: 19407575
[TBL] [Abstract][Full Text] [Related]
26. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.
Markman M; Zanotti K; Peterson G; Kulp B; Webster K; Belinson J
J Clin Oncol; 2003 Dec; 21(24):4611-4. PubMed ID: 14673050
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin.
Furukawa N; Akasaka J; Shigemitsu A; Sasaki Y; Nagai A; Kawaguchi R; Kobayashi H
Arch Gynecol Obstet; 2014 Apr; 289(4):859-64. PubMed ID: 24185939
[TBL] [Abstract][Full Text] [Related]
28. A cohort study of hypersensitivity reaction in patients with epithelial ovarian cancer treated with carboplatin.
Sun T; Li L
Int J Gynecol Cancer; 2019 Mar; 29(3):566-571. PubMed ID: 30833442
[TBL] [Abstract][Full Text] [Related]
29. Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.
Kolomeyevskaya NV; Lele SB; Miller A; Riebandt GC; Blum BL; Odunsi KO; Frederick PJ
Int J Gynecol Cancer; 2015 Jan; 25(1):42-8. PubMed ID: 25356535
[TBL] [Abstract][Full Text] [Related]
30. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.
Vetter MH; Khan A; Backes FJ; Bixel K; Cohn DE; Copeland LJ; Fowler JM; Salani R; Li Q; O'Malley DM
Gynecol Oncol; 2019 Feb; 152(2):316-321. PubMed ID: 30503265
[TBL] [Abstract][Full Text] [Related]
31. Defining the impact of the use of granulocyte colony stimulating factors on the incidence of chemotherapy-induced neutropenia in patients with gynecologic malignancies.
Julius JM; Hammerstrom A; Wei C; Rajesh R; Bodurka DC; Kurian S; Smith JA
J Oncol Pharm Pract; 2017 Mar; 23(2):121-127. PubMed ID: 26692242
[TBL] [Abstract][Full Text] [Related]
32. Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
Jerzak KJ; Deghan Manshadi S; Ng P; Maganti M; McCuaig JM; Bulter M; Oza A; Mackay HJ
J Oncol Pharm Pract; 2018 Mar; 24(2):83-90. PubMed ID: 27856924
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies.
Michikami H; Minaguchi T; Ochi H; Onuki M; Okada S; Matsumoto K; Satoh T; Oki A; Yoshikawa H
J Obstet Gynaecol Res; 2013 Jan; 39(1):330-5. PubMed ID: 22640034
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer.
Iwamoto T; Yuta A; Tabata T; Sugimoto H; Gabazza EC; Hirai H; Kojima S; Okuda M
Biol Pharm Bull; 2012; 35(9):1487-95. PubMed ID: 22975499
[TBL] [Abstract][Full Text] [Related]
35. [Safety and Efficacy of Cisplatin Treatment after Carboplatin Hypersensitivity Reactions in Gynecologic Malignancies].
Matsuoka N; Yokoyama T; Fujimoto E; Sakai M; Okame S; Shiroyama Y; Yokoyama T; Takehara K
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2091-2095. PubMed ID: 29361624
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
[TBL] [Abstract][Full Text] [Related]
37. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer.
Gadducci A; Tana R; Teti G; Zanca G; Fanucchi A; Genazzani AR
Int J Gynecol Cancer; 2008; 18(4):615-20. PubMed ID: 18754135
[TBL] [Abstract][Full Text] [Related]
39. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
O'Cearbhaill R; Zhou Q; Iasonos A; Hensley ML; Tew WP; Aghajanian C; Spriggs DR; Lichtman SM; Sabbatini PJ
Gynecol Oncol; 2010 Mar; 116(3):326-31. PubMed ID: 19944454
[TBL] [Abstract][Full Text] [Related]
40. Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma.
Genc DB; Canpolat C; Berrak SG
Support Care Cancer; 2012 Feb; 20(2):385-93. PubMed ID: 21416159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]